









Markets
/
Stocks
/
nasdaq-grce
/

Grace Therapeutics, Inc

GRCE

3.100USD

-0.020-0.64%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

42.87MMarket Cap

LossP/E TTM



Grace Therapeutics, Inc

3.100

-0.020-0.64%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

155 / 506

Overall Ranking

265 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.875

Target Price

+280.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

Undervalued

The company’s latest PE is -4.06, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 7.78M shares, increasing 11.89% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 409.10K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.42.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.63, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.63

Change



Financials

4.15

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.67

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.66

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.79

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

6.87

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -4.09, which is -26.88% below the recent high of -2.99 and 4.97% above the recent low of -3.88.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 155/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Grace Therapeutics, Inc is 12.00, with a high of 12.50 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.875

Target Price

+280.61%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Grace Therapeutics, Inc

GRCE

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.35, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.38 and the support level at 2.89, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.35

Change

-0.06

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.017

Neutral

RSI(14)

47.780

Neutral

STOCH(KDJ)(9,3,3)

24.344

Neutral

ATR(14)

0.109

High Vlolatility

CCI(14)

-26.181

Neutral

Williams %R

58.537

Sell

TRIX(12,20)

-0.019

Sell

StochRSI(14)

68.828

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

3.088

Buy

MA10

3.157

Sell

MA20

3.130

Sell

MA50

3.156

Sell

MA100

3.032

Buy

MA200

3.070

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 66.51%, representing a quarter-over-quarter increase of 16.06%. The largest institutional shareholder is The Vanguard, holding a total of 409.10K shares, representing 2.96% of shares outstanding, with 33.32% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Shore Pharma LLC

1.19M

Nantahala Capital Management, LLC

1.18M

SS Pharma LLC

931.74K

AIGH Capital Management, LLC.

983.17K

+154.34%

Rajitha Grace 2018 Irrevocable Trust

781.59K

BofA Global Research (US)

494.70K

Kottayil (George)

494.70K

Kavuru (Vimal)

426.32K

The Vanguard Group, Inc.

Star Investors

255.40K

+13.51%

Stonepine Capital Management, LLC

294.55K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.17, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.01. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.